Discrepancy between one-stage and chromogenic factor VIII activity assay results can lead to misdiagnosis of haemophilia A phenotype

Hamostaseologie

Volumn 30, Issue 4, 2010, Pages 207-211

  Oldenburg, Johannes ^a   Pavlova, A ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

Assay discrepancy; Factor 8 gene mutations; FVIII:C; Haemophilia A

Indexed keywords

BLOOD CLOTTING FACTOR 8; CHROMOGENIC SUBSTRATE; THROMBIN;

BLEEDING; CATALYSIS; DIAGNOSTIC ERROR; GENE MUTATION; HEMOPHILIA A; HUMAN; IN VITRO STUDY; IN VIVO STUDY; PHENOTYPE; PROTEIN DEGRADATION; PROTEIN PROTEIN INTERACTION; REVIEW;

EID: 78649982927     PISSN: 07209355     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1619052     Document Type: Review

References (52)

1. Fay PJ. Factor VIII structure and function. Thromb Haemost 1993; 70: 63-67.
2. Lenting PJ, van Mourik JA, Mertens K. The life cycle of coagulation factor VIII in view of its structure and function. Blood 1998; 92: 3983-3996. (Pubitemid 28544310)
3. Brandt JT, Triplett DA. Laboratory assays for factor VIII. In: Zimmerman TS, Ruggeri ZM (eds). Coagulation and bleeding disorders. The role of factor VIII and vWF. New York: Marcel Dekker 1989: 343-357.
4. Langdell RD, Wagner RH, Brinkhous KM. Effect of antihemophilic factor on one-stage clotting tests; a presumptive test for hemophilia and a simple onestage antihemophilic factor assy procedure. J Lab Clin Med 1953; 41: 637-647.
5. Over J. Methodology of the one-stage assay of factor VIII (VIII:C). Scand J Haematol Suppl 1984; 41: 13-24.
6. Biggs R, Eveling J, Richards G. The assay of antihaemophilic- globulin activity. Br J Haematol 1955; 1: 20-34.
7. Barrowcliffe TW. Methodology of the two-stage assay of factor VIII (VIII:C). Scand J Haematol Suppl 1984; 41: 25-38.
8. Rosen S. Assay of factor VIII:C with a chromogenic substrate. Scand J Haematol Suppl 1984; 40: 139-145.
9. Van Dieijen G, van Dieijen-Visser MP, Franssen J, Hemker HC. Spectrophotometric method for the assay of human blood coagulation factor VIII. Haemostasis 1987; 17: 14-24. (Pubitemid 17051339)
10. Hubbard AR, Weller LJ, Bevan SA. Activation profiles of factor VIII in concentrates reflect one-stage/chromogenic potency discrepancies. Br J Haematol 2002; 117: 957-960.
11. Santoro C, Iorio A, Ferrante F et al. Performance of recalibrated ReFacto laboratory standard in the measurement of FVIII plasma concentration via the chromogenic and one-stage assays after infusion of recalibrated ReFacto (B-domain deleted recombinant factor VIII). Haemophilia 2009; 15: 779-787.
12. Oldenburg J, Ananyeva NM, Saenko EL. Molecular basis of haemophilia A. Haemophilia 2004; 10 Suppl 4: 133-139.
13. Oldenburg J, El-Maarri O. New insight into the molecular basis of hemophilia A. Int J Hematol 2006; 83: 96-102. (Pubitemid 44227954)
14. Oldenburg J, Pavlova A. Genetic risk factors for inhibitors to factors VIII and IX. Haemophilia 2006; 12 Suppl 6: 15-22. (Pubitemid 44741498)
15. Rost S, Löffler S, Pavlova A et al. Detection of large duplications within the factor VIII gene by MLPA. J Thromb Haemost 2008; 6: 1996-1999.
16. Haemophilia A Mutation, Structure, Test and Resource Site (HAMSTeRS). Dr. Geoffrey Kemball-Cook (cited 7 July 2010). http://hadb.org.uk/.
17. Poulsen AL, Pedersen LH, Hvas AM et al. Assay discrepancy in mild haemophilia A: entire population study in a National Haemophilia Centre. Haemophilia 2009; 15: 285-289.
18. Vehar GA, Keyt B, Eaton D et al. Structure of human factor VIII. Nature 1984; 312: 337-342.
19. Toole JJ, Knopf JL, Wozney JM et al. Molecular cloning of a cDNA encoding human antihaemophilic factor. Nature 1984; 312: 342-347. (Pubitemid 15209311)
20. Kaufman RJ, Wasley LC, Dorner AJ. Synthesis, processing, and secretion of recombinant human factor VIII expressed in mammalian cells. J Biol Chem 1988; 263: 6352-6362.
21. Tagliavacca L, Moon N, Dunham WR, Kaufman RJ. Identification and functional requirement of Cu(I) and its ligands within coagulation factor VIII. J Biol Chem 1997; 272: 27428-27434.
22. Eaton D, Rodriguez H, Vehar GA. Proteolytic processing of human factor VIII. Correlation of specific cleavages by thrombin, factor Xa, and activated protein C with activation and inactivation of factor VIII coagulant activity. Biochemistry 1986; 25: 505-512.
23. Fay PJ, Anderson MT, Chavin SI, Marder VJ. The size of human factor VIII heterodimers and the effects produced by thrombin. Biochim Biophys Acta 1986; 871: 268-278.
24. Fay PJ, Haidaris PJ, Smudzin TM. Human factor VIIIa subunit structure. Reconstruction of factor VIIIa from the isolated A1/A3-C1-C2 dimer and A2 subunit. J Biol Chem 1991; 266: 8957-8962.
25. Pittman DD, Kaufman RJ. Proteolytic requirements for thrombin activation of anti-hemophilic factor (factor VIII). Proc Natl Acad Sci USA 1988; 85: 2429-2433.
26. Fay PJ, Haidaris PJ, Huggins CF. Role of the COOH-terminal acidic region of A1 subunit in A2 subunit retention in human factor VIIIa. J Biol Chem 1993; 268: 17861-17866.
27. O'Brien LM, Huggins CF, Fay PJ. Interacting regions in the A1 and A2 subunits of factor VIIIa identified by zero-length cross-linking. Blood 1997; 90: 3943-3950.
28. Lollar P, Parker CG. PH-dependent denaturation of thrombin-activated porcine factor VIII. J Biol Chem 1990; 265: 1688-1692.
29. Lollar P, Parker ET. Structural basis for the decreased procoagulant activity of human factor VIII compared to the porcine homolog. J Biol Chem 1991; 266: 12481-12486. (Pubitemid 21907120)
30. Fay PJ, Smudzin TM. Characterization of the interaction between the A2 subunit and A1/A3-C1-C2 dimer in human factor VIIIa. J Biol Chem 1992; 267: 13246-13250.
31. Van Dieijen G, Tans G, Rosing J, Hemker HC. The role of phospholipid and factor VIIIa in the activation of bovine factor X. J Biol Chem 1981; 256: 3433-3442. (Pubitemid 11077003)
32. Mertens K, van Wijngaarden A, Bertina RM. The role of factor VIII in the activation of human blood coagulation factor X by activated factor IX. Thromb Haemost 1985; 54: 654-660. (Pubitemid 16195312)
33. Fay PJ, Beattie T, Huggins CF, Regan LM. Factor VIIIa A2 subunit residues 558-565 represent a factor IXa interactive site. J Biol Chem 1994; 269: 20522-20527.
34. Lapan KA, Fay PJ. Localization of a factor X interactive site in the A1 subunit of factor VIIIa. J Biol Chem 1997; 272: 2082-2088.
35. Duncan EM, Duncan BM, Tunbridge LJ, Lloyd JV. Familial discrepancy between the one-stage and two-stage factor VIII methods in a subgroup of patients with haemophilia A. Br J Haematol 1994; 87: 846-848.
36. Rudzki Z, Duncan EM, Casey GJ et al. Mutations in a subgroup of patients with mild haemophilia A and a familial discrepancy between the one-stage and two-stage factor VIII:C methods. Br J Haematol 1996; 94: 400-406. (Pubitemid 26248003)
37. Parquet-Gernez A, Mazurier C, Goudemand M. Functional and immunological assays of FVIII in 133 haemophiliacs - characterization of a subgroup of patients with mild haemophilia A and discrepancy in 1- and 2-stage assays. Thromb Haemost 1988; 59: 202-206.
38. Gaucher C, Jorieux S, Parquet-Gernez A, Mazurier C. Two mutations of the factor VIII (FVIII) gene, R527W and R531H, are identified in 4 unrelated haemophilia A patients with discrepancy in 1- and 2-stage assays of FVIII coagulant activity. Haemophilia 1996; 2 (Suppl 1): 223a.
39. Montgomery RR, Hathaway WE, Johnson J et al. A variant of von Willebrand's disease with abnormal expression of factor VIII procoagulant activity. Blood 1982; 60: 201-207. (Pubitemid 12085940)
40. Schwaab R, Oldenburg J, Kemball-Cook G et al. Assay discrepancy in mild haemophilia A due to a factor VIII missense mutation (Asn694Ile) in a large Danish family. Br J Haematol 2000; 109: 523-528. (Pubitemid 30415176)
41. Pipe SW, Eickhorst AN, McKinley SH et al. Mild hemophilia A caused by increased rate of factor VIII A2 subunit dissociation: evidence for nonproteolytic inactivation of factor VIIIa in vivo. Blood 1999; 93: 176-183.
42. Pipe SW, Saenko EL, Eickhorst AN et al. Hemophilia A mutations associated with 1-stage/2-stage activity discrepancy disrupt protein-protein interactions within the triplicated A domains of thrombin-activated factor VIIIa. Blood 2001; 97: 685-691.
43. Celie PH, Van Stempvoort G, Jorieux S et al. Substitution of Arg527 and Arg531 in factor VIII associated with mild haemophilia A: characterization in terms of subunit interaction and cofactor function. Br J Haematol 1999; 106: 792-800.
44. Mazurier C, Gaucher C, Jorieux S, Parquet-Gernez A. Mutations in the FVIII gene in seven families with mild haemophilia A. Br J Haematol 1997; 96: 426-427.
45. Keeling DM, Sukhu K, Kemball-Cook G et al. Diagnostic importance of the two-stage factor VIII:C assay demonstrated by a case of mild haemophilia associated with His1954→Leu substitution in the factor VIII A3 domain. Br J Haematol 1999; 105: 1123-1126.
46. th ISTH Congress 2001; Thromb Haemost 2001; OV195.
47. Roelse JC, de Laaf RTM, Mertens K et al. Altered sensitivity towards factor IXa expolains assay discrepancies in plasma of hamophilia A patients with a GLU720 LYS substitution in factor VIII. Thromb Haemost 1999; 82: 5a.
48. th ISTH Congress 2001: Thromb Haemost 2001; P1370.
49. Mumford AD, Laffan M, O'Donnell J et al. A Tyr346→Cys substitution in the interdomain acidic region a1 of factor VIII in an individual with factor VIII:C assay discrepancy. Br J Haematol 2002; 118: 589-594.
50. Trossaert M, Regnault V, Sigaud M et al. Mild hemophilia A with factor VIII assay discrepancy: using thrombin generation assay to assess the bleeding phenotype. J Thromb Haemost 2008; 6: 486-493.
51. Cid AR, Calabuig M, Cortina V et al. One-stage and chromogenic FVIII:C assay discrepancy in mild haemophilia A and the relationship with the mutation and bleeding phenotype. Haemophilia 2008; 14: 1049-1054.
52. Lyall H, Hill M, Westby J et al. Tyr346→Cys mutation results in factor VIII:C assay discrepancy and a normal bleeding phenotype - is this mild haemophilia A? Haemophilia 2008; 14: 78-80.